Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Correction to: Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.

Moore T, Wagner CR, Scurti GM, Hutchens KA, Godellas C, Clark AL, Kolawole EM, Hellman LM, Singh NK, Huyke FA, Wang SY, Calabrese KM, Embree HD, Orentas R, Shirai K, Dellacecca E, Garrett-Mayer E, Li M, Eby JM, Stiff PJ, Evavold BD, Baker BM, Le Poole IC, Dropulic B, Clark JI, Nishimura MI.

Cancer Immunol Immunother. 2018 Feb;67(2):327. doi: 10.1007/s00262-017-2102-z.

PMID:
29264697
2.

Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.

Moore T, Wagner CR, Scurti GM, Hutchens KA, Godellas C, Clark AL, Kolawole EM, Hellman LM, Singh NK, Huyke FA, Wang SY, Calabrese KM, Embree HD, Orentas R, Shirai K, Dellacecca E, Garrett-Mayer E, Li M, Eby JM, Stiff PJ, Evavold BD, Baker BM, Le Poole IC, Dropulic B, Clark JI, Nishimura MI.

Cancer Immunol Immunother. 2018 Feb;67(2):311-325. doi: 10.1007/s00262-017-2073-0. Epub 2017 Oct 20. Erratum in: Cancer Immunol Immunother. 2017 Dec 20;:.

PMID:
29052782
3.

Replenishing Regulatory T Cells to Halt Depigmentation in Vitiligo.

Le Poole IC, Mehrotra S.

J Investig Dermatol Symp Proc. 2017 Oct;18(2):S38-S45. doi: 10.1016/j.jisp.2016.10.023. Review.

PMID:
28941492
4.

Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma.

Klarquist J, Tobin K, Farhangi Oskuei P, Henning SW, Fernandez MF, Dellacecca ER, Navarro FC, Eby JM, Chatterjee S, Mehrotra S, Clark JI, Le Poole IC.

Cancer Res. 2016 Nov 1;76(21):6230-6240. Epub 2016 Sep 12.

5.

Alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 can support immune responses toward tumors overexpressing ganglioside D3 in mice.

Eby JM, Barse L, Henning SW, Rabelink MJ, Klarquist J, Gilbert ER, Hammer AM, Fernandez MF, Yung N, Khan S, Miller HG, Kessler ER, Garrett-Mayer E, Dilling DF, Hoeben RC, Le Poole IC.

Cancer Immunol Immunother. 2017 Jan;66(1):63-75. doi: 10.1007/s00262-016-1920-8. Epub 2016 Oct 27.

PMID:
27787577
6.

Functional cloning of a gp100-reactive T-cell receptor from vitiligo patient skin.

Klarquist J, Eby JM, Henning SW, Li M, Wainwright DA, Westerhof W, Luiten RM, Nishimura MI, Le Poole IC.

Pigment Cell Melanoma Res. 2016 May;29(3):379-84. doi: 10.1111/pcmr.12458. Epub 2016 Mar 4.

PMID:
26824221
7.

Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo.

Webb KC, Tung R, Winterfield LS, Gottlieb AB, Eby JM, Henning SW, Le Poole IC.

Br J Dermatol. 2015 Sep;173(3):641-50. doi: 10.1111/bjd.14016. Epub 2015 Aug 25. Review.

8.

CCL22 to Activate Treg Migration and Suppress Depigmentation in Vitiligo.

Eby JM, Kang HK, Tully ST, Bindeman WE, Peiffer DS, Chatterjee S, Mehrotra S, Le Poole IC.

J Invest Dermatol. 2015 Jun;135(6):1574-1580. doi: 10.1038/jid.2015.26. Epub 2015 Jan 9.

9.

Targeting melanocyte and melanoma stem cells by 8-hydroxy-2-dipropylaminotetralin.

Bonchak JG, Eby JM, Willenborg KA, Chrobak D, Henning SW, Krzywiec A, Johnson SL, Le Poole IC.

Arch Biochem Biophys. 2014 Dec 1;563:71-8. doi: 10.1016/j.abb.2014.07.033. Epub 2014 Aug 14.

10.

Immune responses in a mouse model of vitiligo with spontaneous epidermal de- and repigmentation.

Eby JM, Kang HK, Klarquist J, Chatterjee S, Mosenson JA, Nishimura MI, Garrett-Mayer E, Longley BJ, Engelhard VH, Mehrotra S, Le Poole IC.

Pigment Cell Melanoma Res. 2014 Nov;27(6):1075-85. doi: 10.1111/pcmr.12284. Epub 2014 Jul 21.

11.

Enhanced bleaching treatment: opportunities for immune-assisted melanocyte suicide in vitiligo.

Webb KC, Eby JM, Hariharan V, Hernandez C, Luiten RM, Le Poole IC.

Exp Dermatol. 2014 Aug;23(8):529-33. doi: 10.1111/exd.12449. Epub 2014 Jul 10.

12.

Vitiligo treatment demystified: a flowchart for stratified treatment approaches.

Tung R, Le Poole IC.

Exp Dermatol. 2014 Jul;23(7):469-70. doi: 10.1111/exd.12433.

PMID:
24806714
13.

Preferential secretion of inducible HSP70 by vitiligo melanocytes under stress.

Mosenson JA, Flood K, Klarquist J, Eby JM, Koshoffer A, Boissy RE, Overbeck A, Tung RC, Le Poole IC.

Pigment Cell Melanoma Res. 2014 Mar;27(2):209-20. doi: 10.1111/pcmr.12208. Epub 2014 Jan 13.

14.

A central role for inducible heat-shock protein 70 in autoimmune vitiligo.

Mosenson JA, Eby JM, Hernandez C, Le Poole IC.

Exp Dermatol. 2013 Sep;22(9):566-9. doi: 10.1111/exd.12183. Epub 2013 Jun 20. Review.

15.

Renal angiomyolipoma, fat-poor variant--a clinicopathologic mimicker of malignancy.

Mehta V, Venkataraman G, Antic T, Rubinas TC, Le Poole IC, Picken MM.

Virchows Arch. 2013 Jul;463(1):41-6. doi: 10.1007/s00428-013-1432-2. Epub 2013 Jun 1.

PMID:
23728437
16.

Positioning ganglioside D3 as an immunotherapeutic target in lymphangioleiomyomatosis.

Gilbert ER, Eby JM, Hammer AM, Klarquist J, Christensen DG, Barfuss AJ, Boissy RE, Picken MM, Love RB, Dilling DF, Le Poole IC.

Am J Pathol. 2013 Jul;183(1):226-34. doi: 10.1016/j.ajpath.2013.04.002. Epub 2013 May 10. Erratum in: Am J Pathol. 2013 Nov;183(5):1698.

PMID:
23665200
17.

Mutant HSP70 reverses autoimmune depigmentation in vitiligo.

Mosenson JA, Zloza A, Nieland JD, Garrett-Mayer E, Eby JM, Huelsmann EJ, Kumar P, Denman CJ, Lacek AT, Kohlhapp FJ, Alamiri A, Hughes T, Bines SD, Kaufman HL, Overbeck A, Mehrotra S, Hernandez C, Nishimura MI, Guevara-Patino JA, Le Poole IC.

Sci Transl Med. 2013 Feb 27;5(174):174ra28. doi: 10.1126/scitranslmed.3005127.

18.

A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice.

Mehrotra S, Al-Khami AA, Klarquist J, Husain S, Naga O, Eby JM, Murali AK, Lyons GE, Li M, Spivey ND, Norell H, Martins da Palma T, Onicescu G, Diaz-Montero CM, Garrett-Mayer E, Cole DJ, Le Poole IC, Nishimura MI.

J Immunol. 2012 Aug 15;189(4):1627-38. doi: 10.4049/jimmunol.1103271. Epub 2012 Jul 13.

19.

Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference.

Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CC, Goh BK, Anbar T, Silva de Castro C, Lee AY, Parsad D, van Geel N, Le Poole IC, Oiso N, Benzekri L, Spritz R, Gauthier Y, Hann SK, Picardo M, Taieb A; Vitiligo Global Issue Consensus Conference Panelists.

Pigment Cell Melanoma Res. 2012 May;25(3):E1-13. doi: 10.1111/j.1755-148X.2012.00997.x.

20.

A current viewpoint of lymphangioleiomyomatosis supporting immunotherapeutic treatment options.

Dilling DF, Gilbert ER, Picken MM, Eby JM, Love RB, Le Poole IC.

Am J Respir Cell Mol Biol. 2012 Jan;46(1):1-5. doi: 10.1165/rcmb.2011-0215TR. Review.

PMID:
21940815
21.

Notch signaling regulates mouse and human Th17 differentiation.

Keerthivasan S, Suleiman R, Lawlor R, Roderick J, Bates T, Minter L, Anguita J, Juncadella I, Nickoloff BJ, Le Poole IC, Miele L, Osborne BA.

J Immunol. 2011 Jul 15;187(2):692-701. doi: 10.4049/jimmunol.1003658. Epub 2011 Jun 17.

22.

Heme oxygenase-1 expression protects melanocytes from stress-induced cell death: implications for vitiligo.

Elassiuty YE, Klarquist J, Speiser J, Yousef RM, El Refaee AA, Hunter NS, Shaker OG, Gundeti M, Nieuweboer-Krobotova L, Le Poole IC.

Exp Dermatol. 2011 Jun;20(6):496-501. doi: 10.1111/j.1600-0625.2010.01232.x. Epub 2011 Mar 22.

23.

Topical application of bleaching phenols; in-vivo studies and mechanism of action relevant to melanoma treatment.

Hariharan V, Toole T, Klarquist J, Mosenson J, Longley BJ, Le Poole IC.

Melanoma Res. 2011 Apr;21(2):115-26. doi: 10.1097/CMR.0b013e328343f542.

24.

Reduced skin homing by functional Treg in vitiligo.

Klarquist J, Denman CJ, Hernandez C, Wainwright DA, Strickland FM, Overbeck A, Mehrotra S, Nishimura MI, Le Poole IC.

Pigment Cell Melanoma Res. 2010 Apr;23(2):276-86. doi: 10.1111/j.1755-148X.2010.00688.x. Epub 2010 Feb 19. Erratum in: Pigment Cell Melanoma Res. 2010 Jun;23(3):477. Wainwright, Derek J [corrected to Wainwright, Derek A].

25.

De-N-acetyl GM3 promotes melanoma cell migration and invasion through urokinase plasminogen activator receptor signaling-dependent MMP-2 activation.

Liu JW, Sun P, Yan Q, Paller AS, Gerami P, Ho N, Vashi N, Le Poole IC, Wang XQ.

Cancer Res. 2009 Nov 15;69(22):8662-9. doi: 10.1158/0008-5472.CAN-09-1099. Epub 2009 Nov 10.

26.

Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cells.

Klarquist J, Barfuss A, Kandala S, Reust MJ, Braun RK, Hu J, Dilling DF, McKee MD, Boissy RE, Love RB, Nishimura MI, Le Poole IC.

Am J Pathol. 2009 Dec;175(6):2463-72. doi: 10.2353/ajpath.2009.090525. Epub 2009 Nov 5.

27.

Monobenzyl ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: relevance to skin depigmentation.

Hariharan V, Klarquist J, Reust MJ, Koshoffer A, McKee MD, Boissy RE, Le Poole IC.

J Invest Dermatol. 2010 Jan;130(1):211-20. doi: 10.1038/jid.2009.214.

28.

Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.

Moore TV, Lyons GE, Brasic N, Roszkowski JJ, Voelkl S, Mackensen A, Kast WM, Le Poole IC, Nishimura MI.

Cancer Immunol Immunother. 2009 May;58(5):719-28. doi: 10.1007/s00262-008-0594-2. Epub 2008 Oct 3.

29.

Immortalization of human melanocytes does not alter the de novo properties of nitric oxide to induce cell detachment from extracellular matrix components via cGMP.

Ivanova K, Lambers B, van den Wijngaard R, Le Poole IC, Grigorieva O, Gerzer R, Das PK.

In Vitro Cell Dev Biol Anim. 2008 Sep-Oct;44(8-9):385-95. doi: 10.1007/s11626-008-9113-1. Epub 2008 Jul 2.

PMID:
18594937
30.

Autoimmune etiology of generalized vitiligo.

Le Poole IC, Luiten RM.

Curr Dir Autoimmun. 2008;10:227-43. doi: 10.1159/000131485. Review.

PMID:
18460889
31.

HSP70i accelerates depigmentation in a mouse model of autoimmune vitiligo.

Denman CJ, McCracken J, Hariharan V, Klarquist J, Oyarbide-Valencia K, Guevara-Patiño JA, Le Poole IC.

J Invest Dermatol. 2008 Aug;128(8):2041-8. doi: 10.1038/jid.2008.45. Epub 2008 Mar 13.

32.

Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else?

Schallreuter KU, Bahadoran P, Picardo M, Slominski A, Elassiuty YE, Kemp EH, Giachino C, Liu JB, Luiten RM, Lambe T, Le Poole IC, Dammak I, Onay H, Zmijewski MA, Dell'Anna ML, Zeegers MP, Cornall RJ, Paus R, Ortonne JP, Westerhof W.

Exp Dermatol. 2008 Feb;17(2):139-40; discussion 141-60. doi: 10.1111/j.1600-0625.2007.00666_1.x.

PMID:
18205713
33.

Langerhans cells and dendritic cells are cytotoxic towards HPV16 E6 and E7 expressing target cells.

Le Poole IC, ElMasri WM, Denman CJ, Kroll TM, Bommiasamy H, Lyons Eiben G, Kast WM.

Cancer Immunol Immunother. 2008 Jun;57(6):789-97. Epub 2007 Nov 15.

PMID:
18004565
34.

Therapeutic implications of autoimmune vitiligo T cells.

Oyarbide-Valencia K, van den Boorn JG, Denman CJ, Li M, Carlson JM, Hernandez C, Nishimura MI, Das PK, Luiten RM, Le Poole IC.

Autoimmun Rev. 2006 Aug;5(7):486-92. Epub 2006 May 6. Review.

35.

T-cell avidity and tuning: the flexible connection between tolerance and autoimmunity.

van den Boorn JG, Le Poole IC, Luiten RM.

Int Rev Immunol. 2006 May-Aug;25(3-4):235-58. Review.

36.

Clonal persistence and evolution during a decade of recurrent melanoma.

Wang E, Voiculescu S, Le Poole IC, El-Gamil M, Li X, Sabatino M, Robbins PF, Nickoloff BJ, Marincola FM.

J Invest Dermatol. 2006 Jun;126(6):1372-7.

37.

Expression of gp100 and CDK2 in melanoma cells is not co-regulated by a shared promoter region.

Stennett LS, Riker AI, Kroll TM, ChaMberlin J, Miki T, Nickoloff BJ, Le Poole IC.

Pigment Cell Res. 2004 Oct;17(5):525-32.

PMID:
15357840
38.

Autoimmune aspects of depigmentation in vitiligo.

Le Poole IC, Wañkowicz-Kaliñska A, van den Wijngaard RM, Nickoloff BJ, Das PK.

J Investig Dermatol Symp Proc. 2004 Jan;9(1):68-72. Review.

39.

Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes.

Cassetti MC, McElhiney SP, Shahabi V, Pullen JK, Le Poole IC, Eiben GL, Smith LR, Kast WM.

Vaccine. 2004 Jan 2;22(3-4):520-7.

PMID:
14670335
40.

Expansion of vitiligo lesions is associated with reduced epidermal CDw60 expression and increased expression of HLA-DR in perilesional skin.

Le Poole IC, Stennett LS, Bonish BK, Dee L, Robinson JK, Hernandez C, Hann SK, Nickoloff BJ.

Br J Dermatol. 2003 Oct;149(4):739-48.

PMID:
14616364
41.

Advances in prophylactic cancer vaccine research.

Le Poole IC, Bommiasamy H, Bocchetta M, Kast WM.

Expert Rev Anticancer Ther. 2003 Aug;3(4):537-45. Review.

PMID:
12934665
42.

Cervical cancer vaccines: recent advances in HPV research.

Eiben GL, da Silva DM, Fausch SC, Le Poole IC, Nishimura MI, Kast WM.

Viral Immunol. 2003;16(2):111-21. Review.

PMID:
12828864
43.

Recent progress in tumour vaccine development.

Le Poole IC, Bommiasamy H, Kast WM.

Expert Opin Investig Drugs. 2003 Jun;12(6):971-81. Review.

PMID:
12783601
44.

HPV protein/peptide vaccines: from animal models to clinical trials.

Fausch SC, Da Silva DM, Eiben GL, Le Poole IC, Kast WM.

Front Biosci. 2003 Jan 1;8:s81-91. Review.

PMID:
12456298
45.

Emerging strategies in tumor vaccines.

Le Poole IC, Gerberi MA, Kast WM.

Curr Opin Oncol. 2002 Nov;14(6):641-8. Review.

PMID:
12409655
46.

Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells.

Le Poole IC, Riker AI, Quevedo ME, Stennett LS, Wang E, Marincola FM, Kast WM, Robinson JK, Nickoloff BJ.

Am J Pathol. 2002 Feb;160(2):521-8.

47.

'VIT1', a novel gene associated with vitiligo.

Le Poole IC, Sarangarajan R, Zhao Y, Stennett LS, Brown TL, Sheth P, Miki T, Boissy RE.

Pigment Cell Res. 2001 Dec;14(6):475-84.

48.

Keratinocytes play a role in regulating distribution patterns of recipient melanosomes in vitro.

Minwalla L, Zhao Y, Le Poole IC, Wickett RR, Boissy RE.

J Invest Dermatol. 2001 Aug;117(2):341-7.

49.

Inhibition of melanosome transfer from melanocytes to keratinocytes by lectins and neoglycoproteins in an in vitro model system.

Minwalla L, Zhao Y, Cornelius J, Babcock GF, Wickett RR, Le Poole IC, Boissy RE.

Pigment Cell Res. 2001 Jun;14(3):185-94.

PMID:
11434566
50.

A symbiotic concept of autoimmunity and tumour immunity: lessons from vitiligo.

Das PK, van den Wijngaard RM, Wankowicz-Kalinska A, Le Poole IC.

Trends Immunol. 2001 Mar;22(3):130-6. Review.

PMID:
11286727

Supplemental Content

Loading ...
Support Center